Vienna, Austria

ESTRO 2023

Local time in host city

Programme

10 Sessions
Tuesday
May 16
08:30 - 09:10
Strauss 3
Sophie Espenel, France
Teaching Lecture
Interdisciplinary
Tuesday
May 16
08:30 - 09:10
Lehar 1-3
Paul Sargos, France
Teaching Lecture
Clinical
Tuesday
May 16
08:30 - 09:10
Hall A
Yazid Belkacemi, France
Teaching Lecture
Clinical
Tuesday
May 16
08:30 - 09:10
Strauss 1
Faisal Mahmood, Denmark
Teaching Lecture
Physics
Tuesday
May 16
08:30 - 09:10
Strauss 2
Tuesday
May 16
08:30 - 09:10
Lehar 4
Maeve Kearney, Ireland
Teaching Lecture
RTT
Tuesday
May 16
09:15 - 10:30
Strauss 3
Fiona Mcdonald, United Kingdom
This will be a very interdisciplinary session dedicated to guidelines and good practice in radiation oncology. It will cover numerous aspects of radiation oncology: site specific (oligometastatic NSCLC, postoperative RT for prostate cancer, breast cancer: integration of RT and target therapy, RTT aspects of breast RT, bone met RT), technique/RT modality specific (MR-guided RT systems) and involving different radiation oncology professionals (physicians, physicists, RTT etc.). Some of the guidelines will involve also other societies (ASTRO for lung cancer) and will be practice defining, so you cannot miss this session.
Symposium
Interdisciplinary
Tuesday
May 16
09:15 - 10:30
Schubert
Daan Nevens, Belgium;
Kenton Thompson, Australia
Symposium
Interdisciplinary
Tuesday
May 16
09:15 - 10:30
Lehar 1-3
Alfonso Gomez-Iturriaga, Spain;
Almudena Zapatero, Spain
Oligometastatic disease in prostate cancer has become an emerging situation that we are facing more frequently, mainly due to the incorporation of the new generation of molecular imaging both, in the initial staging of high-risk patients and in the biochemical failure setting, together with increasing availability of high-precision technology in radiotherapy treatments. Specifically, stereotaxic body/ablative radiotherapy (SBRT-SABR) has gained popularity because of a low profile of described complications, an excellent tolerability and a reduced treatment time which is very convenient for patients and departments. This session will cover the available evidence supporting SBRT for oligometastases, including the biological, observational and randomized data, the real impact on clinical outcome, and the controversial, still non-resolved issues.
Debate
Clinical
Tuesday
May 16
09:15 - 10:30
Hall A
Daniel Portik, The Netherlands;
Remi Nout, The Netherlands
Symposium
Clinical
+(event:"ae6e77a9-28d8-ec11-a7b5-00224899b948")